Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 1/20 | 0.60 |
| ▸ | CTSK | P43235 | 5/20 | 0.59 |
| ▸ | CTSB | P07858 | 2/20 | 0.59 |
| ▸ | CASP3 | P42574 | 1/20 | 0.57 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.54 |
| ▸ | CTSL | P07711 | 4/20 | 0.53 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21786912 | 1.00 | REN (0.60) | RENCTSKCTSBCASP3CAPN1 | |
| SCHEMBL19586026 | 0.93 | REN (0.62) | RENCTSKCTSBCASP3CAPN1 | |
| SCHEMBL19586943 | 0.93 | REN (0.62) | RENCTSKCTSBCASP3CAPN1 | |
| SCHEMBL10720680 | 0.91 | CTSK (0.60) | RENCTSKCTSBCASP3CAPN1 | |
| SCHEMBL29530699 | 0.91 | CTSK (0.64) | RENCTSKCTSBCASP3CAPN1 | |
| SCHEMBL19606091 | 0.91 | CTSK (0.64) | RENCTSKCTSBCASP3CAPN1 | |
| SCHEMBL10722584 | 0.90 | CTSK (0.60) | RENCTSKCTSBCASP3CAPN1 | |
| SCHEMBL14838006 | 0.90 | CTSK (0.60) | RENCTSKCTSBCASP3CAPN1 | |
| SCHEMBL10722573 | 0.87 | REN (0.65) | RENCTSKCTSBCASP3CAPN1 | |
| SCHEMBL10722579 | 0.87 | REN (0.65) | RENCTSKCTSBCASP3CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021513-B2 | Peptidomimetics for the treatment of norovirus infection | EMORY UNIVERSITY (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200071354-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF NOROVIRUS INFECTION | EMORY UNIVERSITY (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021513-B2 | Peptidomimetics for the treatment of norovirus infection | VIP, HAVCR2, NGLY1 | REN 894/4885CTSK 1215/4885CTSB 583/4885 |
| US-20200071354-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF NOROVIRUS INFECTION | VIP, HAVCR2, NGLY1 | REN 894/4885CTSK 1215/4885CTSB 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.